Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1587 (115th)

Preservation of Antibiotics for Medical Treatment Act of 2017

passedUnited States· United States Congress· EN

Introduced

16 March 2017

Last action

8 May 2018 · Passed

Status

ASSUMING FIRST SPONSORSHIP - Ms. DeLauro asked unanimous consent that she may hereafter be considered as the first sponsor of H.R. 1587 a bill originally introduced by former Representative Slaughter, for purposes of adding cosponsors and requesting reprintings pursuant to clause 7 of rule XII. Agreed to without objection.

Sponsors

Rep. Slaughter, Louise McIntosh [D-NY-25], Rep. DeLauro, Rosa L. [D-CT-3], Rep. Cicilline, David N. [D-RI-1], Rep. Connolly, Gerald E. [D-VA-11], Rep. DeFazio, Peter A. [D-OR-4], Rep. Deutch, Theodore E. [D-FL-22], Rep. Langevin, James R. [D-RI-2], Rep. Lieu, Ted [D-CA-36], Rep. Lowenthal, Alan S. [D-CA-47], Rep. McCollum, Betty [D-MN-4], Rep. Moulton, Seth [D-MA-6], Rep. Napolitano, Grace F. [D-CA-32], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Speier, Jackie [D-CA-14], Rep. Tsongas, Niki [D-MA-3], Rep. Yarmuth, John A. [D-KY-3], Rep. Jeffries, Hakeem S. [D-NY-8], Rep. Shea-Porter, Carol [D-NH-1], Rep. Clarke, Yvette D. [D-NY-9], Rep. Ellison, Keith [D-MN-5], Rep. Lee, Barbara [D-CA-12], Rep. Moore, Gwen [D-WI-4], Rep. Pingree, Chellie [D-ME-1], Sen. Schiff, Adam B. [D-CA], Rep. Takano, Mark [D-CA-39], Rep. Huffman, Jared [D-CA-2], Rep. Lofgren, Zoe [D-CA-18], Rep. Gabbard, Tulsi [D-HI-2], Rep. Aguilar, Pete [D-CA-33], Rep. Levin, Sander M. [D-MI-12], Rep. Larsen, Rick [D-WA-2], Rep. Evans, Dwight [D-PA-3], Rep. Polis, Jared [D-CO-2], Rep. Rush, Bobby L. [D-IL-1], Rep. Blumenauer, Earl [D-OR-3], Rep. McGovern, James P. [D-MA-2], Rep. Tonko, Paul [D-NY-20], Sen. Welch, Peter [D-VT], Rep. Schakowsky, Janice D. [D-IL-9], Rep. Smith, Adam [D-WA-9], Rep. Cohen, Steve [D-TN-9], Rep. Price, David E. [D-NC-4], Rep. Meng, Grace [D-NY-6], Rep. Gutierrez, Luis V. [D-IL-4], Rep. Kuster, Ann M. [D-NH-2], Rep. Roybal-Allard, Lucille [D-CA-40], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Lipinski, Daniel [D-IL-3]

Subjects

Healthcare

Source updated

11 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Preservation of Antibiotics for Medical Treatment Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to require an applicant for approval of a new animal drug that is a medically important antimicrobial to demonstrate that there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to the nontherapeutic use of the drug. Medically important antimicrobials are drugs intended for use in food-producing animals that contain: (1) specified antibiotics, or (2) certain drugs on the World Health Organization’s list of critically important antimicrobials. Two years after enactment of this bill, the Food and Drug Administration (FDA) must withdraw approval of a drug's nontherapeutic use in food-producing animals unless the FDA makes a determination that, based on the application holder's demonstration or an FDA risk analysis, there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to nontherapeutic use. The FDA must rescind an exemption for investigational use of, or approval of a new drug application for, a medically important antimicrobial for its nontherapeutic use in food-producing animals two years after the exemption is granted or the application for approval is submitted unless there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to nontherapeutic use. A medically important antimicrobial cannot be administered (including through animal feed) to a food-producing animal for disease control unless there is a significant risk that a disease or infection present on the premises will be transmitted to the animal.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 16 March 2017

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 16 March 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 16 March 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 17 March 2017

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  5. 8 May 2018

    Passed

    ASSUMING FIRST SPONSORSHIP - Ms. DeLauro asked unanimous consent that she may hereafter be considered as the first sponsor of H.R. 1587 a bill originally introduced by former Representative Slaughter, for purposes of adding cosponsors and requesting reprintings pursuant to clause 7 of rule XII. Agreed to without objection.

    Source: Floor

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 16 March 2017

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 16 March 2017

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 16 March 2017

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 52 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.